Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + atorvastatin
- Development stage
- Unknown
- Lead developer
- Badr University in Cairo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
empagliflozin + atorvastatin is a combination therapy being investigated for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption and has demonstrated potential in reducing hepatic steatosis. Atorvastatin is an HMG-CoA reductase inhibitor (statin) primarily used for dyslipidemia, which also possesses anti-inflammatory and antioxidant properties that may mitigate liver injury in NASH. This specific combination is being evaluated by Badr University in a Phase 4 clinical trial to assess its efficacy in improving liver stiffness, histological scores, and metabolic parameters in obese diabetic patients.
- Other names
- Empagliflozin plus AtorvastatinEmpagliflozin plus Statin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A1 (Sodium Glucose Cotransporter 1)
Beyond the preview
Go deeper on empagliflozin + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + atorvastatin.